{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:31:24Z","timestamp":1795033884456,"version":"4.10.2"},"reference-count":36,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Extramedullary disease (EMD) in multiple myeloma (MM) is associated with poor outcomes because of aggressive disease kinetics and therapy resistance. The bone marrow (BM) tumor microenvironment (TME) promotes cell survival and drug resistance in marrow-restricted MM, but little is known about the TME in EMD. To characterize the tissue architecture of these tumors, we performed spatial transcriptomics on tumor biopsies. Similar to BM-restricted MM, we identified significant interpatient heterogeneity in plasma cell (PC) expression profiles, although still maintaining a characteristic PC transcriptome. The TME was dominated by macrophages with a suppressive \u201cM2\u201d phenotype. CD8+ T cells frequently expressed exhaustion markers LAG3 and TIGIT, consistent with a suppressive TME. We identified 3 recurrent TME niches based on immune cell composition: immune excluded, immune suppressed, and immune permissive. The immune-excluded niche comprised the bulk of tumors, reflecting spatial exclusion of immune cells. The suppressive extracellular matrix (ECM) from abundant tumor-associated fibroblasts in the immune-suppressive niche may further contribute to T-cell exclusion. Cell-cell interaction modeling revealed a complex, bidirectional network: PC modulated the TME through PGE2 and VEGFB while receiving canonical prosurvival signals through CD38, CXCR4, and BCMA. Notably, TME cells, particularly fibroblasts and macrophages, are predicted to collectively promote the suppressive macrophage phenotype and fibrotic ECM, reinforcing an immunosuppressive milieu that supports local disease progression. These findings reveal the spatial organization of EMD, highlighting niche substitution rather than niche independence, and identify clinically tractable microenvironmental niches and signaling networks in this high-risk myeloma subset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020500","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:04:38Z","timestamp":1782860678000},"page":"6221-6235","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Spatial transcriptomics identifies a suppressive, T-cell\u2013excluded tumor microenvironment in extramedullary myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8142-650X","authenticated-orcid":false,"given":"Nicholas E.","family":"Bingham","sequence":"first","affiliation":[{"name":"1Clinical Haematology, Alfred Health, Melbourne, Australia"},{"name":"2Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1378-4752","authenticated-orcid":false,"given":"Julie R.","family":"Boiko","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Department of Pediatrics, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7055-3119","authenticated-orcid":false,"given":"Daniel C.","family":"Jones","sequence":"additional","affiliation":[{"name":"5Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wong","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Alfred Health, Melbourne, Australia"},{"name":"2Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Khong","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Alfred Health, Melbourne, Australia"},{"name":"2Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridurga","family":"Mithraprabhu","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Alfred Health, Melbourne, Australia"},{"name":"2Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen S.","family":"Ensbey","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-3015","authenticated-orcid":false,"given":"Anna E.","family":"Elz","sequence":"additional","affiliation":[{"name":"6Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-243X","authenticated-orcid":false,"given":"Evan W.","family":"Newell","sequence":"additional","affiliation":[{"name":"5Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"6Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Alfred Health, Melbourne, Australia"},{"name":"2Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Hill","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"6Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"7Faculty of Medicine Nursing and Health Sciences, School of Biomedical Sciences, Monash University, Melbourne, Australia"},{"name":"8Department of Medical Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"1","key":"2026092210520565100_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imr.12011","article-title":"The establishment of the plasma cell survival niche in the bone marrow","volume":"251","author":"Chu","year":"2013","journal-title":"Immunol Rev"},{"issue":"8","key":"2026092210520565100_bib2","doi-asserted-by":"crossref","first-page":"116123","DOI":"10.1016\/j.celrep.2025.116123","article-title":"CD138 and APRIL regulate plasma cell survival, competition, and retention in the bone marrow niche","volume":"44","author":"Park","year":"2025","journal-title":"Cell Rep"},{"issue":"20","key":"2026092210520565100_bib3","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2017-01-761643","article-title":"CD138 mediates selection of mature plasma cells by regulating their survival","volume":"129","author":"McCarron","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2026092210520565100_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"issue":"15","key":"2026092210520565100_bib5","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.2025028896","article-title":"Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics","volume":"146","author":"Yip","year":"2025","journal-title":"Blood"},{"issue":"S2","key":"2026092210520565100_bib6","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/S2152-2650(25)03926-6","article-title":"Poor outcomes in extramedullary multiple myeloma persist despite novel therapies","volume":"25","author":"Bingham","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2026092210520565100_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026092210520565100_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br J Haematol"},{"issue":"28","key":"2026092210520565100_bib9","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026092210520565100_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/curroncol32030182","article-title":"Extramedullary multiple myeloma: challenges and opportunities","volume":"32","author":"Ho","year":"2025","journal-title":"Curr Oncol"},{"issue":"2","key":"2026092210520565100_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"2026092210520565100_bib12","first-page":"890","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"2026092210520565100_bib13","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"2026092210520565100_bib14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/2643-3230.BCD-25-0170","article-title":"Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironment","volume":"7","author":"Anilkumar Sithara","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"2026092210520565100_bib15","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","article-title":"Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors","volume":"38","author":"Jelinek","year":"2024","journal-title":"Leukemia"},{"issue":"20","key":"2026092210520565100_bib16","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026092210520565100_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026092210520565100_bib18","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3324\/haematol.2024.286118","article-title":"Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program","volume":"110","author":"Perrot","year":"2024","journal-title":"Haematologica"},{"issue":"5","key":"2026092210520565100_bib19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11523-025-01168-y","article-title":"Population exposure\u2013response efficacy analysis of elranatamab (PF-06863135) in patients with multiple myeloma","volume":"20","author":"Lon","year":"2025","journal-title":"Target Oncol"},{"issue":"suppl 16","key":"2026092210520565100_bib20","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1200\/JCO.2025.43.16_suppl.7539","article-title":"Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed\/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses","volume":"43","author":"Sidana","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026092210520565100_bib21","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41592-025-02697-0","article-title":"Cell simulation as cell segmentation","volume":"22","author":"Jones","year":"2025","journal-title":"Nat Methods"},{"issue":"1","key":"2026092210520565100_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s43018-025-01072-4","article-title":"A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma","volume":"7","author":"Pilcher","year":"2026","journal-title":"Nat Cancer"},{"issue":"10","key":"2026092210520565100_bib23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/2767-9764.CRC-22-0022","article-title":"Comprehensive characterization of the multiple myeloma immune microenvironment using integrated scRNA-seq, CyTOF, and CITE-seq analysis","volume":"2","author":"Yao","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"1","key":"2026092210520565100_bib24","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1038\/s41467-026-68718-4","article-title":"Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma","volume":"17","author":"Foster","year":"2026","journal-title":"Nat Commun"},{"issue":"1","key":"2026092210520565100_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"2026092210520565100_bib26","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1016\/j.cell.2021.06.024","article-title":"Fibroblasts: origins, definitions, and functions in health and disease","volume":"184","author":"Plikus","year":"2021","journal-title":"Cell"},{"issue":"10","key":"2026092210520565100_bib27","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/bloodadvances.2023011242","article-title":"Immune status and selection of patients for immunotherapy in myeloma: a proposal","volume":"8","author":"Dhodapkar","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"2026092210520565100_bib28","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1038\/s41596-024-01137-1","article-title":"CellPhoneDB v5: inferring cell\u2013cell communication from single-cell multiomics data","volume":"20","author":"Troul\u00e9","year":"2025","journal-title":"Nat Protoc"},{"issue":"5","key":"2026092210520565100_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41408-022-00673-x","article-title":"Structural variants shape the genomic landscape and clinical outcome of multiple myeloma","volume":"12","author":"Ashby","year":"2022","journal-title":"Blood Cancer J"},{"issue":"94","key":"2026092210520565100_bib30","doi-asserted-by":"crossref","first-page":"eadg1094","DOI":"10.1126\/sciimmunol.adg1094","article-title":"TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies","volume":"9","author":"Minnie","year":"2024","journal-title":"Sci Immunol"},{"issue":"26","key":"2026092210520565100_bib31","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/blood.2024025655","article-title":"Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy","volume":"145","author":"Shasha","year":"2025","journal-title":"Blood"},{"issue":"10","key":"2026092210520565100_bib32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nmeth.4437","article-title":"Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations","volume":"14","author":"van den Brink","year":"2017","journal-title":"Nat Methods"},{"issue":"2","key":"2026092210520565100_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/10428190802657751","article-title":"The impact of extramedullary disease at presentation on the outcome of myeloma","volume":"50","author":"Wu","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"2026092210520565100_bib34","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/blood-2010-02-266296","article-title":"An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation","volume":"116","author":"MacDonald","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2026092210520565100_bib35","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood.V122.21.1946.1946","article-title":"Bone marrow fibrosis in patients with multiple myeloma: a new prognostic factor for survival?","volume":"122","author":"Hallgrimsdottir","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2026092210520565100_bib36","doi-asserted-by":"crossref","first-page":"24506","DOI":"10.18632\/oncotarget.15534","article-title":"Pirfenidone normalizes the tumor microenvironment to improve chemotherapy","volume":"8","author":"Polydorou","year":"2017","journal-title":"Oncotarget"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6221\/2588335\/blooda_adv-2026-020500-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6221\/2588335\/blooda_adv-2026-020500-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:19Z","timestamp":1790088739000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6221\/569441\/Spatial-transcriptomics-identifies-a-suppressive-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020500","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,11]]}}}